Differential molecular mechanism of the docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells

  • Home
  • Convegni
  • Differential molecular mechanism of the docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells

Differential molecular mechanism of the docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells

Posted on 17 dicembre 2014

Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano M, Lo Nigro C: “Differential molecular mechanism of the docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells”, 54 Congresso Nazionale della Società Italiana di Cancerologia (SIC), Bologna, 1-4 ottobre 2012.